세계의 결핵 백신 치료 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

The global market for Tuberculosis Vaccine Treatment was estimated to be worth US$ 80.42 million in 2024 and is forecast to a readjusted size of US$ 98 million by 2031 with a CAGR of 2.9% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Tuberculosis Vaccine Treatment cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guerin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme. Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.In 2024, global Tuberculosis Vaccine Treatment production reached approximately 318 m units, with an average global market price of around US$ 0.21 perunit

The global TB burden remains high, with WHO reporting over 10 million new cases annually, concentrated mainly in Asia and Africa, providing strong demand for tuberculosis vaccines. Governments are implementing immunization programs and public health policies to increase vaccination coverage and support new vaccine R&D through policy and funding incentives. Annual reports of leading vaccine manufacturers show sustained R&D investment, capacity expansion, and export growth, maintaining steady global market expansion. Brokerage research indicates that the need for multidrug-resistant TB (MDR-TB) prevention and new trackable vaccine management systems will further enhance vaccine penetration in public health and clinical prevention.

Tuberculosis vaccine R&D and manufacturing face challenges such as technical complexity, long clinical trial cycles, and strict regulatory approvals. Annual reports highlight that raw material supply, cold-chain logistics, and storage requirements impose high demands on cost and supply stability. Vaccination coverage in some regions is limited by insufficient public health resources, patient adherence, and vaccine accessibility, while policy adjustments, price controls, and reimbursement coverage changes may affect market revenue. Differing international regulations and approval requirements increase uncertainties for overseas market expansion.

Downstream demand is extending toward full-population and lifecycle vaccination and immunization management. Newborns and children remain the core target population, while high-risk adult protection needs are growing. Digital vaccine management and remote monitoring platforms facilitate end-to-end tracking of vaccine administration, improving adherence and efficacy evaluation. Brokerage reports suggest that new MDR-TB vaccines and products with monitorable immune responses will be key differentiation points, while integration with digital management and policy incentives is expected to create long-term market value in public health and individual disease prevention.

This report aims to provide a comprehensive presentation of the global market for Tuberculosis Vaccine Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Tuberculosis Vaccine Treatment by region & country, by Type, and by Application.

The Tuberculosis Vaccine Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis Vaccine Treatment.

Market Segmentation

By Company

• Merck
• Japan BCG Lab
• Serum Institute of India
• AJ Vaccines
• BioFarma
• GreenSignal Bio Pharma
• China National Biotec
• Biomed Lublin
• Taj Pharmaceuticals
• Ataulpho de Paiva
• IVAC
• Queen Saovabha Mem. Inst
• Microgen

Segment by Type

• Immune Vaccine
• Therapy Vaccine

Segment by Application

• Self-Procurement
• UNICEF
• Other

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Tuberculosis Vaccine Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Tuberculosis Vaccine Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Tuberculosis Vaccine Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Tuberculosis Vaccine Treatment Product Introduction
• 1.2 Global Tuberculosis Vaccine Treatment Market Size Forecast
  • 1.2.1 Global Tuberculosis Vaccine Treatment Sales Value (2020-2031)
  • 1.2.2 Global Tuberculosis Vaccine Treatment Sales Volume (2020-2031)
  • 1.2.3 Global Tuberculosis Vaccine Treatment Sales Price (2020-2031)
• 1.3 Tuberculosis Vaccine Treatment Market Trends & Drivers
  • 1.3.1 Tuberculosis Vaccine Treatment Industry Trends
  • 1.3.2 Tuberculosis Vaccine Treatment Market Drivers & Opportunity
  • 1.3.3 Tuberculosis Vaccine Treatment Market Challenges
  • 1.3.4 Tuberculosis Vaccine Treatment Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Tuberculosis Vaccine Treatment Players Revenue Ranking (2024)
• 2.2 Global Tuberculosis Vaccine Treatment Revenue by Company (2020-2025)
• 2.3 Global Tuberculosis Vaccine Treatment Players Sales Volume Ranking (2024)
• 2.4 Global Tuberculosis Vaccine Treatment Sales Volume by Company Players (2020-2025)
• 2.5 Global Tuberculosis Vaccine Treatment Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Tuberculosis Vaccine Treatment Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Tuberculosis Vaccine Treatment Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Tuberculosis Vaccine Treatment
• 2.9 Tuberculosis Vaccine Treatment Market Competitive Analysis
  • 2.9.1 Tuberculosis Vaccine Treatment Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Tuberculosis Vaccine Treatment Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis Vaccine Treatment as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Immune Vaccine
  • 3.1.2 Therapy Vaccine
• 3.2 Global Tuberculosis Vaccine Treatment Sales Value by Type
  • 3.2.1 Global Tuberculosis Vaccine Treatment Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Tuberculosis Vaccine Treatment Sales Value, by Type (2020-2031)
  • 3.2.3 Global Tuberculosis Vaccine Treatment Sales Value, by Type (%) (2020-2031)
• 3.3 Global Tuberculosis Vaccine Treatment Sales Volume by Type
  • 3.3.1 Global Tuberculosis Vaccine Treatment Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Tuberculosis Vaccine Treatment Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Tuberculosis Vaccine Treatment Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Tuberculosis Vaccine Treatment Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Self-Procurement
  • 4.1.2 UNICEF
  • 4.1.3 Other
• 4.2 Global Tuberculosis Vaccine Treatment Sales Value by Application
  • 4.2.1 Global Tuberculosis Vaccine Treatment Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Tuberculosis Vaccine Treatment Sales Value, by Application (2020-2031)
  • 4.2.3 Global Tuberculosis Vaccine Treatment Sales Value, by Application (%) (2020-2031)
• 4.3 Global Tuberculosis Vaccine Treatment Sales Volume by Application
  • 4.3.1 Global Tuberculosis Vaccine Treatment Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Tuberculosis Vaccine Treatment Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Tuberculosis Vaccine Treatment Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Tuberculosis Vaccine Treatment Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Tuberculosis Vaccine Treatment Sales Value by Region
  • 5.1.1 Global Tuberculosis Vaccine Treatment Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Tuberculosis Vaccine Treatment Sales Value by Region (2020-2025)
  • 5.1.3 Global Tuberculosis Vaccine Treatment Sales Value by Region (2026-2031)
  • 5.1.4 Global Tuberculosis Vaccine Treatment Sales Value by Region (%), (2020-2031)
• 5.2 Global Tuberculosis Vaccine Treatment Sales Volume by Region
  • 5.2.1 Global Tuberculosis Vaccine Treatment Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Tuberculosis Vaccine Treatment Sales Volume by Region (2020-2025)
  • 5.2.3 Global Tuberculosis Vaccine Treatment Sales Volume by Region (2026-2031)
  • 5.2.4 Global Tuberculosis Vaccine Treatment Sales Volume by Region (%), (2020-2031)
• 5.3 Global Tuberculosis Vaccine Treatment Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 5.4.2 North America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 5.5.2 Europe Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Tuberculosis Vaccine Treatment Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 5.7.2 South America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 6.3.2 United States Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 6.4.2 Europe Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 6.5.2 China Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 6.6.2 Japan Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 6.7.2 South Korea Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Tuberculosis Vaccine Treatment Sales Value, 2020-2031
  • 6.9.2 India Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Merck
  • 7.1.1 Merck Company Information
  • 7.1.2 Merck Introduction and Business Overview
  • 7.1.3 Merck Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Merck Tuberculosis Vaccine Treatment Product Offerings
  • 7.1.5 Merck Recent Development
• 7.2 Japan BCG Lab
  • 7.2.1 Japan BCG Lab Company Information
  • 7.2.2 Japan BCG Lab Introduction and Business Overview
  • 7.2.3 Japan BCG Lab Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Japan BCG Lab Tuberculosis Vaccine Treatment Product Offerings
  • 7.2.5 Japan BCG Lab Recent Development
• 7.3 Serum Institute of India
  • 7.3.1 Serum Institute of India Company Information
  • 7.3.2 Serum Institute of India Introduction and Business Overview
  • 7.3.3 Serum Institute of India Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Serum Institute of India Tuberculosis Vaccine Treatment Product Offerings
  • 7.3.5 Serum Institute of India Recent Development
• 7.4 AJ Vaccines
  • 7.4.1 AJ Vaccines Company Information
  • 7.4.2 AJ Vaccines Introduction and Business Overview
  • 7.4.3 AJ Vaccines Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 AJ Vaccines Tuberculosis Vaccine Treatment Product Offerings
  • 7.4.5 AJ Vaccines Recent Development
• 7.5 BioFarma
  • 7.5.1 BioFarma Company Information
  • 7.5.2 BioFarma Introduction and Business Overview
  • 7.5.3 BioFarma Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 BioFarma Tuberculosis Vaccine Treatment Product Offerings
  • 7.5.5 BioFarma Recent Development
• 7.6 GreenSignal Bio Pharma
  • 7.6.1 GreenSignal Bio Pharma Company Information
  • 7.6.2 GreenSignal Bio Pharma Introduction and Business Overview
  • 7.6.3 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Offerings
  • 7.6.5 GreenSignal Bio Pharma Recent Development
• 7.7 China National Biotec
  • 7.7.1 China National Biotec Company Information
  • 7.7.2 China National Biotec Introduction and Business Overview
  • 7.7.3 China National Biotec Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 China National Biotec Tuberculosis Vaccine Treatment Product Offerings
  • 7.7.5 China National Biotec Recent Development
• 7.8 Biomed Lublin
  • 7.8.1 Biomed Lublin Company Information
  • 7.8.2 Biomed Lublin Introduction and Business Overview
  • 7.8.3 Biomed Lublin Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Biomed Lublin Tuberculosis Vaccine Treatment Product Offerings
  • 7.8.5 Biomed Lublin Recent Development
• 7.9 Taj Pharmaceuticals
  • 7.9.1 Taj Pharmaceuticals Company Information
  • 7.9.2 Taj Pharmaceuticals Introduction and Business Overview
  • 7.9.3 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Offerings
  • 7.9.5 Taj Pharmaceuticals Recent Development
• 7.10 Ataulpho de Paiva
  • 7.10.1 Ataulpho de Paiva Company Information
  • 7.10.2 Ataulpho de Paiva Introduction and Business Overview
  • 7.10.3 Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Offerings
  • 7.10.5 Ataulpho de Paiva Recent Development
• 7.11 IVAC
  • 7.11.1 IVAC Company Information
  • 7.11.2 IVAC Introduction and Business Overview
  • 7.11.3 IVAC Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 IVAC Tuberculosis Vaccine Treatment Product Offerings
  • 7.11.5 IVAC Recent Development
• 7.12 Queen Saovabha Mem. Inst
  • 7.12.1 Queen Saovabha Mem. Inst Company Information
  • 7.12.2 Queen Saovabha Mem. Inst Introduction and Business Overview
  • 7.12.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Offerings
  • 7.12.5 Queen Saovabha Mem. Inst Recent Development
• 7.13 Microgen
  • 7.13.1 Microgen Company Information
  • 7.13.2 Microgen Introduction and Business Overview
  • 7.13.3 Microgen Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 Microgen Tuberculosis Vaccine Treatment Product Offerings
  • 7.13.5 Microgen Recent Development

8 Industry Chain Analysis

• 8.1 Tuberculosis Vaccine Treatment Industrial Chain
• 8.2 Tuberculosis Vaccine Treatment Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Tuberculosis Vaccine Treatment Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Tuberculosis Vaccine Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer